The hottest event of the week was the official kick-off of the volumn-based procurement of the third batch of pharmaceutical products organized in China, with 86 specifications started to be acquired the basic information. Regarding other aspects, no new drugs other than Humanwell’s Class 1 new drug remimazolam besylate were approved for marketing. Now, let’s review the hot events of the pharmaceutical industry this week. The news involved 6 sections: approval, R&D, performance, volumn-based procurement, listing, and transactions that happened during July 20-24, including 24 pieces.
Performance
17. Novartis released its 2020 H1 performance report on July 21. Its net sales reached USD23.63 billion, growing by 6% year on year; its net income reached USD4.04 billion, growing by 11% year on year; the sales of its core product: Entresto reached USD1.149 billion, growing by 50%; the sale of Cosentyx reached USD1.874 billion, growing by 15%; the sales of Zolgensma reached USD375 million, and the sales of Kisqali reached USD320 million.
18. Roche released its 2020 H1 performance report on July 23. Its total income reached CHF29.3 billion, down by 4% year on year; wherein, the income of its pharmaceutical business reached CHF23.2 billion, down by 4% year on year. Roche was seriously affected by COVID-19 in 2020 Q2, with sales revenue experiencing negative growth for the first time, down by 4%; in particular, its sales revenue seriously declined by 15% in May.
Volumn-based Procurement
19. Sunshine Medical Procurement All-In-One released the Notice on Conducting the Acquisition of Basic Information on Some Pharmaceutical Products on July 21 to prepare for the volumn-based procurement of the third batch of pharmaceutical products. The 86 specifications (of 56 varieties) involved are consistent with the previous list for provinces to submit the procurement quantity. The requirements on the pharmaceutical products for Read More
(All Rights Reserved)